These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32917825)

  • 21. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
    De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
    J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Spinal muscular atrophy treated with nusinersen].
    Boesen MS; Albrechtsen S; Born AP
    Ugeskr Laeger; 2019 Jan; 181(2):. PubMed ID: 30618374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory outcomes post nusinersen in spinal muscular atrophy type 1.
    Gonski K; Fitzgerald DA
    Pediatr Pulmonol; 2021 May; 56(5):807-808. PubMed ID: 33316146
    [No Abstract]   [Full Text] [Related]  

  • 24. Limited Assessment of Respiratory Muscle Response to Nusinersen Treatment in Infants with Spinal Muscular Atrophy.
    Chacko A; Sly PD; Gauld L
    Am J Respir Crit Care Med; 2020 Mar; 201(5):624. PubMed ID: 31747298
    [No Abstract]   [Full Text] [Related]  

  • 25. [Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy].
    Mao SS; Feng YJ; Xu L; Yao M; Xia Y; Jin JN; Wang LS; Chen TT; Chen XY; Zhang Y; Zhang H; Jiang Y; Li HB; Long Q; Gao F
    Zhonghua Er Ke Za Zhi; 2022 Jul; 60(7):688-693. PubMed ID: 35768357
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcomes in type 1 spinal muscular atrophy on nusinersen: A single center experience.
    Kaltman J; Kern-Smith E; Zhang C; Figueroa J; Ritchey M; Razdan R; Verma S
    Clin Neurophysiol; 2020 Dec; 131(12):2793-2794. PubMed ID: 33130439
    [No Abstract]   [Full Text] [Related]  

  • 27. Reply to Chacko
    LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
    Am J Respir Crit Care Med; 2020 Mar; 201(5):624-626. PubMed ID: 31747301
    [No Abstract]   [Full Text] [Related]  

  • 28. A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen.
    Bielsky AR; Fuhr PG; Parsons JA; Yaster M
    Paediatr Anaesth; 2018 Dec; 28(12):1105-1108. PubMed ID: 30284761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nusinersen in spinal muscular atrophy type 1 from neonates to young adult: 1-year data from three Asia-Pacific regions.
    Chan SH; Chae JH; Chien YH; Ko TS; Lee JH; Lee YJ; Nam SO; Jong YJ
    J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1244-1246. PubMed ID: 33574081
    [No Abstract]   [Full Text] [Related]  

  • 30. A 5-center experience with intrathecal administration of nusinersen in SMA1 in Italy letter to the editor of european journal of pediatric neurology regarding the manuscript "single-center experience with intrathecal administration of nusinersen in children with spinal muscular atrophy type 1" written by pechmann and colleagues".
    Sansone VA; Pane M; Messina S; Bruno C; D'Amico A; Albamonte E; Catteruccia M; Sframeli M; Pedemonte M; Vita G; Bertini E; Mercuri E;
    Eur J Paediatr Neurol; 2018 Jul; 22(4):729-731. PubMed ID: 29673809
    [No Abstract]   [Full Text] [Related]  

  • 31. Effect of Nusinersen on Respiratory Muscle Function in Different Subtypes of Type 1 Spinal Muscular Atrophy.
    LoMauro A; Mastella C; Alberti K; Masson R; Aliverti A; Baranello G
    Am J Respir Crit Care Med; 2019 Dec; 200(12):1547-1550. PubMed ID: 31433957
    [No Abstract]   [Full Text] [Related]  

  • 32. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen.
    Menard J; Seferian AM; Fleurence E; Barzic A; Binoche A; Labouret G; Coutier L; Vuillerot C; Bieleu BM; Gomez Garcia de la Banda M; Corvol H; Servais L; Taytard J
    Pediatr Pulmonol; 2022 Jun; 57(6):1505-1512. PubMed ID: 35307979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Nusinersen in the treatment of spinal muscular atrophy].
    Sinkó G; Kiss Z; Kalman B
    Ideggyogy Sz; 2018 Mar; 71(3-04):90-94. PubMed ID: 29889467
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
    J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementing a Global Expanded Access Program (EAP) for Infantile-Onset Spinal Muscular Atrophy (Type I): Understanding the Imperative, Impact and Challenges.
    Yong J; Moffett M; Lucas S
    J Neuromuscul Dis; 2019; 6(2):227-231. PubMed ID: 31127730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 37. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
    Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
    Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy.
    Sarıkaya Uzan G; Paketçi C; Günay Ç; Edem P; Özsoy Ö; Hız Kurul S; Yiş U
    Neuropediatrics; 2022 Oct; 53(5):321-329. PubMed ID: 35871521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A severely affected adult type 2 spinal muscular atrophy patient treated with risdiplam.
    Schön M; Domingues S; Moreno T; Oliveira Santos M
    Neurol Sci; 2023 Apr; 44(4):1449-1450. PubMed ID: 36472753
    [No Abstract]   [Full Text] [Related]  

  • 40. Case of spinal muscular atrophy type 0 with mild prognosis.
    Kitaoka H; Shitara Y; Uchida Y; Kondo U; Omori I
    Pediatr Int; 2020 Jan; 62(1):106-107. PubMed ID: 31916364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.